NEW YORK (GenomeWeb News) – Applied Biosystems said today that the Genome Institute of Singapore has acquired three SOLiD DNA sequencing systems for use in studying the genetic underpinnings of cancer and other diseases.
GIS already had one SOLiD system on site, according to ABI. Researchers at the institute are studying how structural variants, such as copy number variations, single-base duplications, inversions, translocations, insertions, and deletions, contribute to the development of cancer.
"We evaluated several technologies for this kind of research, and concluded that the SOLiD System fits very well with our paired end di-tag technology and will provide us with a platform that enables rapid, accurate and cost-effective study of a variety of types of genetic variants present in cancer genomes," Yijun Ruan, associate director for genomic technologies at GIS, said in a statement.
Financial terms of the purchase were not disclosed.